Holly Kramer1,2,3, Richard Cooper4. 1. Department of Public Health Sciences, Loyola University Chicago, 2160 S. First Avenue, Maywood, IL, 60153, USA. hkramer@lumc.edu. 2. Medicine, Division of Nephrology and Hypertension, Loyola University Chicago, Maywood, IL, USA. hkramer@lumc.edu. 3. Hines VA Medical Center, Hines, IL, USA. hkramer@lumc.edu. 4. Department of Public Health Sciences, Loyola University Chicago, 2160 S. First Avenue, Maywood, IL, 60153, USA.
Abstract
PURPOSE OF REVIEW: The Systolic Blood Pressure Intervention Trial demonstrated significant decreases in cardiovascular events and total mortality with intensive systolic blood pressure lowering in adults with high cardiovascular risk in the absence of diabetes but benefits were accompanied by increased risk of adverse events. RECENT FINDINGS: Over 100,000 deaths and 46,000 cases of heart failure may be prevented annually if intensive systolic blood pressure lowering is implemented in 17 million US adults who are age 50 years and older, and have high cardiovascular risk in the absence of diabetes and meet eligibility for the Systolic Blood Pressure Intervention Trial. However, the benefits of intensive SBP lowering will be accompanied by an excess of 43,000 cases of electrolyte abnormalities and 88,000 cases of acute kidney injury. Physicians should consider implementation of intensive systolic blood pressure lowering in appropriate patients who understand the risks and benefits of this intervention.
PURPOSE OF REVIEW: The Systolic Blood Pressure Intervention Trial demonstrated significant decreases in cardiovascular events and total mortality with intensive systolic blood pressure lowering in adults with high cardiovascular risk in the absence of diabetes but benefits were accompanied by increased risk of adverse events. RECENT FINDINGS: Over 100,000 deaths and 46,000 cases of heart failure may be prevented annually if intensive systolic blood pressure lowering is implemented in 17 million US adults who are age 50 years and older, and have high cardiovascular risk in the absence of diabetes and meet eligibility for the Systolic Blood Pressure Intervention Trial. However, the benefits of intensive SBP lowering will be accompanied by an excess of 43,000 cases of electrolyte abnormalities and 88,000 cases of acute kidney injury. Physicians should consider implementation of intensive systolic blood pressure lowering in appropriate patients who understand the risks and benefits of this intervention.
Authors: J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti Journal: Lancet Date: 1997-09-13 Impact factor: 79.321
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Adam P Bress; Rikki M Tanner; Rachel Hess; Lisandro D Colantonio; Daichi Shimbo; Paul Muntner Journal: J Am Coll Cardiol Date: 2015-11-09 Impact factor: 24.094
Authors: Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers Journal: Lancet Date: 2015-11-07 Impact factor: 79.321